Cullinan Therapeutics, Inc.
CGEM
Rank in Stocks
#10257
Cullinan Therapeutics, Inc. operates as a biopharmaceutical firm actively... Cullinan Therapeutics, Inc. operates as a biopharmaceutical firm actively advancing its therapeutic candidates through clinical trials. This company is focused on developing innovative treatments primarily for cancer, including those that leverage the immune system (immuno-oncology). Its current roster of investigational drugs comprises CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. Patrick A. Baeuerle founded the organization on September 15, 2016, and it is presently headquartered in Cambridge, Massachusetts.
Share Price
$11.73
Last synced: 2026-11-09
Market Cap
$720.90M
Change (1 day)
3.71%
Change (1 year)
50.38%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Cullinan Therapeutics, Inc. (CGEM)
Category
Healthcare
EPS for Cullinan Therapeutics, Inc. (CGEM)
EPS as of June 2026 TTM: $-3.37
According to Cullinan Therapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $-3.37. At the end of 2025 the company had an EPS of $-3.72, a decrease compared to its 2024 EPS of $-3.11.
EPS history for Cullinan Therapeutics, Inc. from 2018 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-3.37 | -9.41% |
| 2025 | $-3.72 | 19.61% |
| 2024 | $-3.11 | -15.72% |
| 2023 | $-3.69 | -250.00% |
| 2022 | $2.46 | -266.22% |
| 2021 | $-1.48 | 24.37% |
| 2020 | $-1.19 | -93.96% |
| 2019 | $-19.70 | 11.05% |
| 2018 | $-17.74 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -564.69% |
US
|
|
| $-7.07 | 109.79% |
US
|
|
| $-5.29 | 56.97% |
AU
|
|
| $12.88 | -482.20% |
BE
|
|
| $21.56 | -739.76% |
NL
|
Questions about Cullinan Therapeutics, Inc.'s earnings per share (EPS)
What is Cullinan Therapeutics, Inc.'s earnings per share (EPS)?
Cullinan Therapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $-3.37, as of Jun 2026.
What was Cullinan Therapeutics, Inc.'s earnings per share (EPS) in 2025?
In 2025, Cullinan Therapeutics, Inc.'s earnings per share (EPS) was $-3.72, compared with $-3.11 in 2024.
How has Cullinan Therapeutics, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Cullinan Therapeutics, Inc.'s earnings per share (EPS) was highest in 2022 ($2.46) and lowest in 2025 ($-3.72).
How does Cullinan Therapeutics, Inc.'s earnings per share (EPS) compare with similar companies?
Cullinan Therapeutics, Inc.'s earnings per share (EPS) ($-3.37) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.